Janssen cleared to market Invokamet XR
RARITAN, N.J. — Janssen Pharmaceuticals Inc. has received approval from the Food and Drug Administration for Invokamet XR, a type 2 diabetes medication. The Johnson & Johnson subsidiary said Invokamet XR, a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release, is indicated for first-line use as an adjunct to diet and exercise to
